Carlos Hartmann, MD
Infectious Disease · Covington, LANPI 1962769141
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,642 of the $9,425 with a category attached, or 81.1%. Viiv Healthcare Company accounts for 69.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $6,166 and has fallen 98.1% since, to $118 in 2025.
Across 59 payments — averaging $159.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$7K
- KCI USA, Inc.$2K
- Gilead$276
- AbbVie$268
- Astellas Pharma US Inc$149
- Shionogi Inc$125
- plus $284 from 5 others
What the payments were for
- Speaking & faculty fees$7,64281%
- Travel & lodging$1882%
- Food & beverage$1,59517%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 34 | $6,532 |
| KCI USA, Inc. | 1 | $1,792 |
| Gilead | 9 | $276 |
| AbbVie(2 entities) | 2 | $268 |
| Astellas Pharma US Inc | 2 | $149 |
| Shionogi Inc | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $115 |
| Merck | 4 | $73 |
| Johnson & Johnson | 3 | $62 |
| Janssen Scientific Affairs, LLC | 1 | $18 |
| Napo Pharmaceuticals Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,425 in reported general payments places this provider in the 85th percentile of 105 infectious disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 114 | $439,174 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 36 | $137,561 |
| JulucaDolutegravir/Rilpivirine | 39 | $135,391 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 29 | $133,546 |
| TivicayDolutegravir Sodium | 44 | $105,651 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $105,388 |
| DovatoDolutegravir Sodium/Lamivudine | 18 | $57,970 |
| DescovyEmtricitabine/Tenofov Alafenam | 15 | $36,602 |
| Darunavir | 11 | $18,590 |
| ErtapenemErtapenem Sodium | 28 | $12,959 |
| Daptomycin | 43 | $12,275 |
| Valganciclovir Hcl | 33 | $10,834 |
| Atovaquone | 17 | $6,125 |
| Linezolid | 28 | $4,602 |
| Cefepime Hcl | 12 | $1,897 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $276 | $613,336165 claims |
| Viiv Healthcare CompanyJuluca, Tivicay, Dovato | $6,532 | $299,012101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 105 infectious disease providers in Louisiana.
Other infectious disease in Covington
- Camille BitarCovington$3K
- Michael HillCovington$1K
- Bridget OryCovington$860
- Hector Brunet RodriguezShreveport$592K
- Guillermo Padilla-PinedaShreveport$106K
- Eric EhrensingNew Orleans$97K
- Meredith ClementNew Orleans$93K
- Rebecca LillisNew Orleans$60K
- Stephanie TaylorNew Orleans$25K
- Edwin SwiatloNew Orleans$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.